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Purpose: To investigate the effects and mechanisms of glucosamine (GlcN) on the proliferation of retinal pigment
epithelial cells in response to epidermal growth factor (EGF).
Methods: Cell proliferation was measured in the human retinal pigment epithelial cell line (ARPE-19) cells with the 4-
[3-(4iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene  disulfonate  (WST-1)  assay  and  cell  counting.  The
results were confirmed in human donor cells with the carboxyfluorescein diacetate succinimidyl ester cell proliferation
assay (CFSE) cell proliferation assay. In ARPE-19 cells, cell-cycle progression was determined by flow cytometry; the
protein levels of cell cycle regulators and heat shock protein 90 (Hsp90) were measured by western blotting; the levels
and branching of N-glycans were assessed using the  L-Phaseolus vulgaris agglutinin lectin-binding assay; and the
modulation of N-glycans on EGF receptor (EGFR) was examined by western blotting.
Results: GlcN inhibited retinal pigment epithelium (RPE) proliferation in a dose-dependent manner. During cell-cycle
progression induced by EGF, GlcN caused delays at the G1–S and G2–M transitions without affecting cell viability. GlcN
modulated  the  level  and  branching  of  N-glycans  on  EGFR,  suppressed  phosphorylation  of  EGFR,  and  reduced
phosphorylation of extracellular signal-regulated kinases, erine/threonine protein kinase, and the signal transducer and
activator of transcription 3 (STAT3). GlcN had only minor effects on the expression of Hsp90, Grp78, and transcription
factor CHOP/GADD 153 markers of nonspecific stress in the endoplasmic reticulum.
Conclusions: GlcN effectively suppressed proliferation of RPE cells in vitro. This effect appeared to be achieved through
modification of N-glycans on EGFR. Further research into the role of GlcN as a potential agent for the prevention and
treatment  of  RPE-mediated  ocular  proliferative  disorders,  such  as  proliferative  vitreoretinopathy,  and  other  EGF-
dependent proliferative cell-growth disorders, is warranted.
Proliferative  vitreoretinopathy  (PVR)  is  the  most
common cause of treatment failure in rhegmatogenous retinal
detachment [1]. The mechanisms underlying the pathogenesis
of PVR are unknown, but are presumed to include either
sustained  or  discordant  growth-factor  responses  that
accelerate the proliferation, migration, and contraction of the
retinal pigment epithelium (RPE) [2]. Accumulating evidence
indicates that epidermal growth factor (EGF)–EGF receptor
(EGFR) signaling is involved in diverse cellular processes,
including the growth, differentiation, and survival of RPE
cells  in  vitro  [3–9].  Furthermore,  the  activation  of  EGF–
EGFR  signaling  seems  to  be  an  important  feature  of  the
pathogenesis of PVR [10–12].
Our  previous  studies  have  shown  that  glucosamine
(GlcN)  has  an  anti-inflammatory  effect  in  ocular
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inflammatory disorders [13,14]. In addition, GlcN has been
reported  to  inhibit  the  growth  of  various  cell  types  [15].
Because  GlcN  is  an  inhibitor  of  the  biosynthesis  and
processing of N-linked oligosaccharides and causes dramatic
and  reversible  changes  in  the  nature  of  the  lipid-linked
oligosaccharides of glycoproteins [16], we hypothesized that
GlcN might exert an antiproliferative effect on human retinal
pigment epithelial cell line (ARPE)-19 cells and that reduced
branching and levels of N-glycans on surface growth-factor
receptors might be involved in the mechanism. Demonstrating
the validity of this hypothesis could provide support for the
use  of  GlcN  as  a  potential  agent  for  the  prevention  and
treatment  of  RPE-mediated  ocular  proliferative  disorders,
such as PVR. The purpose of the study, therefore, was to
examine the effects and mechanism of action of GlcN on EGF-
induced  proliferation,  in  vitro,  in  human  donor  cells  and
ARPE-19 cells, respectively.
METHODS
Cell culture: ARPE-19 cells were obtained from the American
Type Culture Collection (Manassas, VA) and maintained in
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2559Dulbecco’s modified Eagle’s medium (F-12) supplemented
with 4 mM L-glutamine, 10% fetal bovine serum (FBS), 100
U/ml penicillin, and 100 mg/ml streptomycin at 37 °C in 5%
CO2 in air. The culture medium was replaced twice weekly.
Cytotoxicity assay: ARPE-19 cells were seeded into 24-well
plates at a density of 2×104 cells per well in 1 ml Dulbecco’s
modified Eagle’s medium and 10% FBS. The medium was
changed after 24 h, and GlcN was added in concentrations
between 0 mM and 140 mM. After 24 h, ARPE-19 cells were
trypsinized and stained with 2% trypan blue (1:1 vol/vol) for
5  min.  Viable  (unstained)  and  dead  (stained)  cells  were
counted from each well by hemocytometer. Experiments were
performed in triplicate and repeated three times. At least 400
cells were counted in each well.
Proliferation assays:
4-[3-(4iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate cell proliferation assay
—The cell proliferation test was based on the ready-to-use cell
proliferation  reagent  4-[3-(4iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene  disulfonate
(WST-1;  Roche  Diagnostics,  Indianapolis,  IN).  After
treatment for 48 h with various concentrations of GlcN in
serum-free medium with 10 ng/ml EGF stimulation, 10 μl of
WST-1 reagent were added to the medium in each well. The
cells were incubated in a humidified atmosphere at 37 °C in
5% CO2/95% air for 1 h, the multititer plate was shaken
thoroughly for 1 min, and absorbances were read at 450 nm.
The  background  absorbance  was  measured  in  wells
containing only the dye solution and culture medium. Cell
proliferation  data  were  obtained  from  at  least  three
experiments with at least six wells at each concentration in
separate  96-well  plates.  The  mean  optical  density  values
corresponding to the untreated controls were taken as 100%.
The results were expressed as the percentage of the optical
density of treated cells relative to that of untreated controls.
Cell counting—During stimulation with 10% FBS or 10
ng/ml EGF, ARPE-19 cells were treated with 2.5 mM or 5 mM
GlcN for 1–5 days. At the end of the treatment period, the cells
were trypsinized and washed twice with ice-cold phosphate
buffer solution (PBS; 137 mM NaCl, 2.7 mM KCl, 100 mM
Na2HPO4,  2  mM  KH2PO4,  pH  7.4).  For  each  sample,  an
aliquot  of  cells  was  counted  using  a  hemocytometer  to
determine the cell number.
Carboxyfluorescein diacetate succinimidyl ester cell
proliferation  assay—For  staining  with  cell  proliferation
assay  (CFSE;  Invitrogen/Molecular  Probes,  Eugene,  OR),
1×107/ml human donor RPE cells in PBS were incubated at
37 °C for 15 min with 1.0 μM CFSE in 0.1% FBS/PBS. The
human donor RPE cells were obtained from the cryopreserved
cells used in our previous study [11]. Staining was terminated
by the addition of culture medium containing 10% FBS. The
cells were washed once in 10% FBS/PBS and resuspended in
culture  medium  at  2×106/ml.  Stained  cells  (2×105/well,
100 μl) were cultured overnight in 60 mm dishes with culture
medium  containing  20%  FBS.  The  medium  was  then
exchanged with one containing 10 ng/ml EGF with 2.5 mM,
5.0 mM GlcN, or 30 mM glucose, and incubated for 3 days.
At the end of the treatment period, the cells were trypsinized
and  analyzed  on  a  FACScan  flow  cytometer  (Becton,
Dickinson, & Co., Sunnyvale, CA).
The CFSE passively diffuses into cells. It is colorless and
nonfluorescent  until  the  acetate  groups  are  cleaved  by
intracellular  esterases  to  yield  highly  fluorescent
carboxyfluorescein  succinimidyl  ester.  The  succinimidyl
ester  group  reacts  with  intracellular  amines,  forming
fluorescent conjugates that are well retained and can be fixed
with aldehyde fixatives. The dye–protein adducts that form in
labeled cells are retained by the cells. The label is inherited
and shared by daughter cells after cell division, and is not
transferred to adjacent cells in a population. Therefore, the
cells undergoing the processes of cell division show gradually
decreasing intensity of fluorescence, and the lower level of
staining indicates a rapidly proliferating cell population.
Cell viability assays:
Detection of apoptosis—Apoptosis-mediated death of
GlcN-treated cells was examined by a double-staining method
with  fluorescein  isothiocyanate  (FITC)-labeled  annexin  V
(Invitrogen,  Carlsbad,  CA)/propidium  iodide  (PI;  Sigma-
Aldrich;  St.  Louis,  MO).  ARPE-19  cells  were  starved  by
culture  in  serum-free  medium  for  24  h  and  then  were
stimulated with EGF (with or without treatment with GlcN for
5 days). We changed the medium each day. After treatment
with 2.5 mM or 5.0 mM GlcN, the cells were trypsinized and
counted. A fraction of the cells (2×105) was collected by
centrifugation, and the pellet was washed twice with PBS. The
cell pellet was resuspended, incubated for 15 min in 100 μl of
labeling solution (5 μl of annexin V in 100 μl of Hepes buffer
[10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 5 mM CaCl2]),
then collected by centrifugation and washed twice with PBS.
Finally,  400  μl  of  Hepes  buffer  containing  2.5  μl  of  PI
(50 μg/ml) was added, and the samples were analyzed on a
FACScan flow cytometer.
Cell-cycle analysis: ARPE-19 cells were treated with GlcN
for 24 h in serum-free medium, and the cell cycle was arrested
by  incubation  for  24  h  in  culture  medium  containing
aphidicolin (1 μg/ml; Sigma-Aldrich). The cells were then
released  from  arrest  by  incubation  in  drug-free  culture
medium containing 10 ng/ml EGF and harvested with trypsin
at various time points, washed twice with PBS, fixed in ice-
cold 70% (v/v) ethanol, and stored at 4 °C until use. Before
flow-cytometric analysis, the cells were washed with PBS and
centrifuged, and the cell pellets were resuspended in RNase
(1 mg/ml) for 30 min. The cells were then stained for 15 min
with PI in PBS (final concentration 40 μg/ml) before analysis
with a FACScan flow cytometer using CellQuest software
(Becton, Dickinson, & Co.)
Western blot analysis: At the end of the treatment period, the
cells were washed twice with PBS and detached by scraping.
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in cold lysis buffer (50 mM Tris-HCl [pH 7.5], 2% sodium
dodecyl sulfate [SDS], 1 mM phenylmethylsulfonyl fluoride,
and  10  μl/ml  protease  inhibitors).  The  lysates  were
centrifuged at 12,000× g for 10 min, and the clear supernatant
was removed into fresh Eppendorf tubes. The total protein was
estimated using the Pierce bicinchoninic acid (BCA; Pierce,
Rockford, IL) protein assay. The samples (20 μg of lysate)
were then boiled for 5 min, loaded onto a sodium dodecyl
sulfate/10%  polyacrylamide  gel,  separated
electrophoretically,  and  transferred  to  a  polyvinylidene
difluoride (PVDF) membrane (Immobilon; Millipore Corp.,
Bedford, MA). The membranes were blocked with 5% (w/v)
milk in Tris-buffered saline (50 mM Tris.HCl, pH 7.4 and
150 mM NaCl) containing 0.05% Tween-20 (TBST) for 60–
120 min at room temperature on a shaking table. The blots
were incubated for 60 min at room temperature with primary
antibody against the following: cyclin A, cyclin D1, cyclin E,
retinoblastoma  protein  (Rb),  p-RB  (Ser  807/811),  AKT,
phosphorylated  AKT  (Ser473),  STAT3,  phosphorylated
STAT3, and EGFR (all antibodies from BD PharMingen, San
Diego, CA); CDK2 and CDK4 (diluted 1:1,000 in TBST;
Santa Cruz Biotechnology, Santa Cruz, CA); ERK1, ERK2,
and phosphorylated ERK1/2 (diluted 1:2,000 in TBST; BD
PharMingen); Hsp27, Hsp70, and Hsp90 (diluted 1:1,000 in
TBST; Santa Cruz Biotechnology); Grp78 and CHOP-GADD
(diluted 1:1,000 in TBST; Santa Cruz Biotechnology); total
EGFR  and  active  EGFR  (diluted  1:1,000  in  TBST;  BD
PharMingen); β-catenin (diluted 1:2,000 in TBST; Santa Cruz
Biotechnology);  or  glyceraldehyde-3-phosphate
dehydrogenase  (diluted  1:20,000  in  TBST;  Rockland
Immunochemicals,  Gilbertsville,  PA).  After  extensive
washing,  the  membranes  were  blotted  with  horseradish-
peroxidase-conjugated secondary antibody (1:1,000; Jackson
ImmunoResearch Laboratories, West Grove, PA) for 1 h at
room temperature. The peroxidase activity on the membrane
was  visualized  on  X-ray  film  by  a  standard  enhanced
chemiluminescence procedure.
Flow-cytometric  analysis  of  EGFR  activation:
Phosphorylated EGFR (p-EGFR) and total EGFR levels were
quantitatively measured by flow cytometry with BD Phosflow
reagents (BD Biosciences) according to the manufacturer’s
protocol. Briefly, 1×106 cells were cultured in serum-free
medium containing 30 mM glucose, 2.5 mM GlcN, or 5.0 mM
GlcN for 24 h. The cells were then stimulated with 10 ng/ml
EGF at 37 °C for 30 min and harvested with PBS-based
enzyme-free  dissociation  buffer  (Invitrogen).  After
centrifugation, the cell pellets were washed twice in PBS and
immediately fixed for 10 min at 37 °C by the addition of an
equal volume of Phosflow Fix Buffer I. After centrifugation,
the cells were permeabilized with 1 ml of BD Phosflow Perm
Buffer III, incubated for 30 min on ice, and washed twice with
stain buffer. The cell pellet was resuspended in 100 μl of stain
buffer  containing  the  primary  antibody.  The  following
primary antibodies were used: phycoerythrin (PE)-conjugated
anti-total-EGFR (cells were not permeabilized for total EGFR
detection)  and  Alexa-Fluor-647-conjugated  anti-p-EGFR
(Y845; BD PharMingen). After incubation for 30 min in the
dark, the cells were washed twice with 1 mL of stain buffer
before analysis performed by FACScan flow cytometer.
Western blot analysis of EGFR activation: ARPE-19 cells
were  cultured  to  80%  confluence.  The  medium  was  then
changed, and the cells were cultured with the addition of
2 μg/ml tunicamycin, 30 mM glucose, or 5 mM GlcN in
serum-free medium for a further 24 h. Then the cells were
stimulated  with  EGF  for  5  min.  At  the  final  time  point,
proteins contained in the whole cell lysates were analyzed by
western blotting.
Western blot analysis of β-catenin expression: ARPE-19 cells
were  cultured  to  80%  confluence.  The  medium  was  then
changed, and the cells were cultured with the addition of
2.5 mM or 5 mM GlcN in serum-free medium for a further 24
h. Then the cells were stimulated with EGF for 24 h. At the
final time point, proteins contained in the whole cell lysates
were analyzed by western blotting with probes against β-
catenin.
Lectin-binding analysis: Phytohemagglutinin-L (L-PHA) is a
plant lectin that specifically binds β-1,6-GlcNAc-branched N-
glycans. Flow-cytometric measurement of L-PHA binding to
ARPE-19 cells was used to characterize the branching of N-
linked  oligosaccharides  on  surface  proteins.  Cells  with
increased metabolic flux through the hexosamine pathway
(i.e., treated with 30 mM N-acetyl-glucosamine [GlcNAc] or
30 mM glucose) were used as a positive control. Cells treated
with tunicamycin, an inhibitor of protein N-glycosylation,
were  used  as  the  negative  control.  ARPE-19  cells  were
cultured to 80% confluence. The medium was then changed,
and  the  cells  were  cultured  with  the  addition  of  2  μg/ml
tunicamycin, 30 mM GlcNAc, 30 mM glucose, 2.5 mM GlcN,
or 5 mM GlcN in medium containing 10% FBS for a further
24 h. The cells were then harvested with PBS-based enzyme-
free dissociation buffer (Invitrogen). After centrifugation, the
cell pellets were rinsed, resuspended in PBS, and incubated
with FITC–L-PHA (10 μg/ml; Vector, Burlingame, CA) and
1% BSA (BSA) in PBS on ice for 15 min. After the cells had
been washed once with four volumes of 1% BSA/PBS, they
were analyzed on a FACScan flow cytometer.
Markers of stress in the endoplasmic reticulum: ARPE-19
cells were treated with 30 mM glucose, 5 mM GlcN, or 1 μM
thapsigargin as the positive control. The levels of expression
of Hsp90, Grp78, and CHOP-GADD were determined by
western blotting after treatment for 24 h and 48 h.
Statistical analysis: All data are expressed as mean±standard
deviation (SD). The difference in inhibition of ARPE-19 cell
proliferation after treatment with the various concentrations
of GlcN was compared with one-way ANOVA (ANOVA).
The  ARPE-19  cell  count  observed  at  each  day  was  also
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were revealed by one-way ANOVA, post-hoc analyses were
performed with Tukey’s test. Linear regression analysis was
performed to test the time-trend of the cell count. In addition,
two-way ANOVA was performed to check whether the slopes
of the time-trend curves were different among the control cells
and among those treated with 2.5 mM and 5.0 mM GlcN. Two-
sided  comparisons  were  implemented  with  SPSS  15.0
software (SPSS Inc., Chicago, IL) and evaluated at the 0.05
level of significance.
RESULTS
Cytotoxicity of glucosamine: The results of the trypan blue
exclusion assay to determine the lethal concentration (LC)50
Figure  1.  Viability  of  human  retinal
pigment epithelial cell line (ARPE-19)
cells  and  determination  of  the  LC50
concentration in the presence of GlcN.
ARPE-19  cells  were  cultured  in
Dulbecco’s  modified  Eagle’s  medium
and 10% fetal bovine serum (FBS). The
medium was changed after 24 h, and
glucosamine  (GlcN)  was  added  in
concentrations between 0 mM and 140
mM.  After  24  h,  viability  was
determined with 2% trypan blue. The
LC50 was 39.0 mM. An LC50 value is the
concentration of a material that will kill
50% of the test cells.
Figure  2.  Inhibition  of  human  retinal
pigment epithelial cell line (ARPE-19)
cell  proliferation  by  glucosamine
(GlcN), measured with a colorimetric
test  (WST-1)  and  cell  counting.  A:
ARPE-19 cells were cultured for 48 h at
different  concentration  of  GlcN.  The
proliferation results are expressed as a
mean  percentage  of  control
proliferation. B: After 24 h culture, the
ARPE-19 cells were exposed to 2.5 mM
or 5.0 mM GlcN for 3 days. During this
time, the medium was not changed. The
ARPE-19 cells were exposed to 2.5 mM
or 5.0 mM GlcN with either 10% fetal
bovine  serum  (FBS;  C)  or  10  ng/ml
endothelial  growth  factor  (EGF;  D)
stimulation for 5 days (the medium with
fresh  GlcN  included  was  changed
daily). The results are the means±SD of
five  independent  experiments.  The
difference in inhibition of ARPE-19 cell
proliferation  among  various
concentrations of GlcN was compared
with  one-way  ANOVA  (ANOVA);
Tukey’s  test  was  used  for  post-hoc
analyses. * p<0.05, ** p<0.01, and ***
p<0.001 versus the control.
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2562of GlcN are shown in Figure 1. The LC50 concentration was
39.0 mM, and approximately 3% and 6.5% cytotoxicity was
observed  with  concentrations  of  2.5  mM  and  5  mM,
respectively.
Suppression  of  epidermal  growth  factor-induced
proliferation of RPE cells by GlcN in vitro: As shown in
Figure 2A, cell proliferation was significantly lower in cells
treated with GlcN at concentrations of 1.0 mM or higher (all
p<0.05) than in control cells. The proliferation was reduced
by  3.4%,  14.3%,  26.3%,  34.5%,  and  44.6%  at  0.5  mM,
1.0 mM, 2.5 mM, 5.0 mM, and 10.0 mM GlcN, respectively.
The IC50 concentration was 13.6 mM (Figure 2A). All further
experiments were conducted with 2.5 mM and 5.0 mM GlcN
because these concentrations had a relatively large effect on
proliferation but were minimally cytotoxic.
To further explore the effects of GlcN on proliferation of
RPE  cells,  ARPE-19  cells  were  cultured  in  medium
containing 0, 2.5, or 5.0 mM GlcN for 3 days. The slope of
the growth curve decreased significantly during the first day
after treatment, but gradually returned to parallel the slope of
the control cells (Figure 2B). The uptake of GlcN by the cells
led to a reduced concentration of GlcN in the medium and a
tapering of the antiproliferative effect. Therefore, we changed
the medium (including fresh GlcN) each day and stimulated
Figure 3. Effects of glucosamine (GlcN)
on human retinal pigment epithelial cell
line (ARPE-19) cell viability shown by
calcein/PI flow cytometric analysis. A:
ARPE-19 cells were treated for 5 days
with 2.5 mM or 5.0 mM GlcN under
serum-free  conditions,  and  apoptotic
cells were measured as the percentage of
annexin V-positive/PI-positive cells. B:
The quantitative data collected from the
fluorescent images are expressed as the
mean  percentage±SD  from  three
individual experiments.
Figure 4. Effects of glucosamine (GlcN)
on  epidermal  growth  factor  (EGF)-
induced  cell-cycle  progression  in
human  retinal  pigment  epithelial  cell
line (ARPE-19) cells. A: ARPE-19 cells
were deprived of serum for 24 h and then
harvested  at  the  indicated  times  after
stimulation with 10 ng/ml EGF with or
without  the  addition  of  GlcN.  B:
ARPE-19  cells  were  synchronized  in
early S phase by serum deprivation and
aphidicolin treatment and harvested at
the indicated times after release from the
aphidicolin block by stimulation with 10
ng/ml EGF with or without the addition
of GlcN. The percentages of cells in the
G0–G1,  S,  and  G2–M  phases  were
determined. The data are the means±SD
of three independent experiments.
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2563proliferation with 10% FBS (Figure 2C) or EGF (10 ng/ml,
Figure 2D). Except for the measurement at day 2, significant
differences in the number of cells among the three groups were
found (all p<0.05) after stimulation with EGF (Figure 2D). By
day 5 in the presence of EGF, the cell counts were reduced by
60.5% and 88% with 2.5 mM and 5.0 mM GlcN, respectively.
The antiproliferative effect of glucosamine is not related to
apoptosis: To investigate whether the antiproliferative effect
of  GlcN  was  related  to  apoptosis,  we  used  annexin  V/PI
staining (Figure 3A,B) to measure apoptosis after 24 h of
treatment with 2.5 mM or 5.0 mM GlcN under serum-free
conditions.  The  results  showed  that  GlcN  did  not  induce
apoptosis in the ARPE-19 cells.
TABLE 1. PERCENTAGE OF HUMAN RETINAL PIGMENT EPITHELIAL CELL LINE (ARPE-19) CELLS IN EACH CELL-CYCLE WITHOUT
APHIDICOLIN TREATMENT (CELLS SYNCHRONIZED IN G0–G1)
Cell cycle phase EGF Mean±SD EGF+GlcN 2.5 mM Mean±SD EGF+GlcN 5.0 mM Mean±SD
G0/G1
0 h 77.57±3.88 81.06±4.05 63.67±3.18
6 h 80.33±4.02 69.13±3.46 65.51±3.28
12 h 75.87±3.79 84.74±4.24 77.89±3.89
18 h 42.86±2.14 62.58±3.13 75.65±3.78
24 h 68.66±3.43 55.18±2.76 64.34±3.22
S
0 h 8.24±0.41 7.2±0.36 21.18±1.06
6 h 6.44±0.32 14.48±0.72 18.22±0.91
12 h 14.52±0.73 9.65±0.48 12.68±0.63
18 h 36.21±1.81 28.75±1.44 16.61±0.83
24 h 11.0±0.55 24.89±1.24 28.46±1.42
G2/M
0 h 14.18±0.71 11.74±0.59 15.14±0.76
6 h 13.23±0.66 16.39±0.82 16.27±0.81
12 h 9.61±0.48 5.61±0.28 9.43±0.47
18 h 20.94±1.05 8.68±0.43 7.75±0.39
24 h 20.34±1.02 19.93±1 7.19±0.36
          Abbreviations: EGF represents epidermal growth factor; SD represents standard deviation.
TABLE 2. PERCENTAGE OF HUMAN RETINAL PIGMENT EPITHELIAL CELL LINE (ARPE-19) CELLS IN EACH CELL-CYCLE AFTER
RELEASE WITH APHIDICOLIN TREATMENT
Cell cycle phase EGF Mean±SD EGF+GlcN 2.5 mM Mean±SD EGF+GlcN 5.0 mM Mean±SD
G0/G1
0 h 79.2±3.96 80.66±4.03 82.01±4.1
4 h 25.5±1.27 22.43±1.12 23.27±1.16
8 h 42.09±2.1 29.05±1.45 25.29±1.26
12 h 77.72±3.89 76.63±3.83 60.99±3.05
S
0 h 15.54±0.78 11.66±0.58 9.13±0.46
4 h 55.95±2.8 67.42±3.37 70.79±3.54
8 h 8.03±0.4 25.57±1.28 30.46±1.52
12 h 12.69±0.63 5.95±0.3 9.41±0.47
G2/M
0 h 5.27±0.26 7.69±0.38 8.87±0.44
4 h 18.55±0.93 10.15±0.51 5.94±0.3
8 h 49.88±2.49 45.38±2.27 44.25±2.21
12 h 9.59±0.48 17.42±0.87 29.6±1.48
           Abbreviations: EGF represents epidermal growth factor; SD represents standard deviation.
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2564GlcN delays EGF-induced cell-cycle progression: We next
examined the effects of GlcN on the progression of RPE cells
through the cell cycle after the cells had been synchronized in
G0–G1 phase. At 18 h after stimulation with EGF, ~36% of the
ARPE-19 control cells had entered S phase, whereas ~29% of
the cells treated with 2.5 mM GlcN and only ~17% of the cells
treated with 5.0 mM GlcN had done so (Figure 4A and Table
1). At 24 h, ~20% of the control cells and the cells treated with
2.5 mM GlcN progressed to G2–M phase, although only ~25%
of the cells treated with 2.5 mM GlcN were still in S phase
(Figure  4A).  In  contrast,  ~28%  of  the  cells  treated  with
5.0 mM GlcN remained in S phase at 24 h, and very few
(<10%) had entered G2–M phase. A similar slowing of cell-
cycle  progression  was  observed  when  the  cells  were
synchronized in S phase rather than G0–G1 phase (Figure 4B
and Table 2).
GlcN altered the expression of cyclins and p27: The effects
of GlcN on expression of several cyclins, cyclin-dependent
kinases  (CDKs),  and  CDK  inhibitors  were  detected;  the
results are shown in Figure 5. After stimulation with EGF, a
marked immediate increase in the amount of cyclin D1 in the
control cells was noted, whereas expression of cyclin D1 was
delayed in the cells treated with GlcN. Treatment with GlcN
also caused the levels of cyclin E, which increase as cells enter
G1 phase and decline throughout M phase, to decline at a
slower rate than in control cells after stimulation with EGF.
Figure 5. Effects of glucosamine (GlcN)
on  the  expression  of  cell-cycle
regulators.  Human  retinal  pigment
epithelial cell line (ARPE-19) cells were
deprived of serum for 24 h, stimulated
with 10 ng/ml epidermal growth factor
(EGF) with or without the addition of
GlcN for the indicated times, lysed, and
subjected  to  immunoblotting  analysis
with  antibodies  directed  against  the
indicated  proteins.  The  data  are
representative  of  at  least  three
independent experiments.
Figure  6.  Effects  of  GlcN  on  EGF-
stimulated  phosphorylation  of  ERK,
AKT,  and  STAT3.  Human  retinal
pigment epithelial cell line (ARPE-19)
cells were pretreated with 2.5 mM or 5.0
mM glucosamine (GlcN) under serum-
free conditions for 24 h and incubated
for a further 30 min in the presence or
absence of 10 ng/ml epidermal growth
factor (EGF). The same blot was probed
with anti-phospho antibody or anti-total
antibodies for ERK, AKT, and STAT3.
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this was delayed in GlcN-treated cells in parallel with their
delayed entry into S phase. Degradation of the CDK inhibitor
p27 is required for cell progression through G0–G1 phase to S
phase.  However,  the  abundance  of  this  protein  remained
higher in GlcN-treated cells than in control cells during their
progression through S and G2–M phases. The levels and time
courses of CDK2 and CDK4 expression were not affected by
treatment with GlcN. During the G1–S transition, the cyclin
D1–CDK4 complex and the cyclin E–CDK2 complex mediate
Rb hyperphosphorylation, which results in E2F release and
the transcription of growth-associated genes. The 807/811
phosphorylation sites of EGFR were examined because they
occur in the region of E2F/pRb binding and may play a key
role in the interaction between these two molecules. A reduced
level of hyperphosphorylated Rb was observed in the GlcN-
treated cells.
GlcN inhibited phosphorylation of ERK1/2, AKT, and STAT3:
As shown in Figure 6, stimulation of the control cells by EGF
resulted in enhanced phosphorylation of ERK1/2, AKT, and
STAT3. Preincubation of the cells with GlcN in the medium
diminished the EGF-dependent phosphorylation of ERK1/2,
AKT, and STAT3 in a dose-dependent manner.
GlcN suppressed EGF-induced increases in β-catenin: We
also performed western blot analysis to examine the effects of
GlcN on the EGF-induced expression in β-catenin (Figure 7).
GlcN had no effect on the expression of β-catenin in the
absence of EGF, but it effectively suppressed the increased
expression of β-catenin induced by EGF.
Inhibition of EGFR phosphorylation in GlcN-treated RPE
cells:  Upon  stimulation  with  EGF,  the  levels  of
phosphorylation of EGFR observed on the surface of cells
treated with GlcN were lower than on the control cells (Figure
8A) and on cells that had been treated with 30 mM glucose as
a positive control. There also appeared to be a slightly reduced
level of total EGFR on the surface of the GlcN-treated cells
(Figure 8B). Western blot analysis of the levels of total and
phosphorylated EGFR (Figure 8C) showed a similar reduction
in the total and phosphorylated form of EGFR on the surface
after treatment with GlcN, whereas high levels of glucose
increased  the  expression  and  phosphorylation  of  EGFR.
Tunicamycin, on the other hand, had little effect on the total
EGFR but markedly reduced its phosphorylation.
Inhibition of N-Linked glycosylation in GlcN-treated RPE
cells: Compared with the positive control cells, which had
been treated with GlcNAc or glucose, cells cultured with GlcN
for 24 h showed decreased binding of L-PHA (Figure 9A). A
greater reduction in L-PHA binding was observed in the cells
treated with 5.0 mM GlcN than in those treated with 2.5 mM
GlcN (Figure 9B). Similarly, EGF receptors at 170 kDa (the
molecular mass corresponding to the glycosylated form) were
evident in the control cells as determined by western blotting;
and treatment with 30 mM glucose increased the level of 170-
kDa  receptors  after  incubation  for  24  h  (Figure  9C).  In
contrast, when the medium was changed to one containing
GlcN, a 145-kDa EGFR protein became increasingly apparent
in a dose-dependent manner. Finally, we observed that human
donor RPE cells with higher levels and greater branching of
N-glycans on EGFR proliferated more rapidly than did cells
with lower levels, as determined by staining with CFSE and
flow cytometry (Figure 9D).
Anti-proliferation  effect  of  GlcN  not  from  endoplasmic
reticulum  stress:  To  determine  whether  the  effects  of
inhibition  of  N-Linked  glycosylation  of  EGFR  and  anti-
proliferation in GlcN-treated RPE cells were due to GlcN-
induced nonspecific stress in the endoplasmic reticulum (ER),
we evaluated the expression of Hsp90, Hsp70, Hsp27, Grp78,
and CHOP-GADD (markers of stress in the ER) in GlcN-
treated ARPE-19 cells. Western blot analyses showed only
minor effects on the expression of Grp78, and CHOP-GADD
when cells were treated with 5 mM GlcN, in contrast to the
marked increases in their expression caused by treatment with
thapsigargin  (TG)  or  30  mM  Glucose  (Figure  10).  The
expression of Hsp90 increased in the presence of 30 mM
glucose but not GlcN. The expression of Hsp70 and Hsp27
was scarcely affected by the addition of any of the stimulants.
These results indicated that at 5 mM, GlcN did not induce high
levels of ER stress in the RPE cells, which suggested that the
observed effects of GlcN on RPE cells were not nonspecific
effects from ER stress.
Figure  7.  Glucosamine  (GlcN)
suppressed  epidermal  growth  factor
(EGF)-induced increases in β-catenin.
The  human  retinal  pigment  epithelial
cell line (ARPE-19) cells were cultured
to 80% confluence, treated with 2.5 mM
or 5 mM GlcN in serum-free medium for
24  h,  then  stimulated  with  EGF  for
further 24 h and probed with antibody
against β-catenin.
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The purpose of this study was to test the hypothesis that GlcN
inhibits  EGF-induced  RPE  proliferation,  in  vitro,  and  to
Figure  8.  Effects  of  glucosamine  (GlcN)  on  transactivation  of
epidermal growth factor receptor (EGFR). Human retinal pigment
epithelial cell line (ARPE-19) cells were treated with 2.5 mM or 5.0
mM GlcN, or 30 mM glucose for 24 h, stimulated with 10 ng/ml
EGF, and stained with PE-conjugated anti-total-EGFR antibody and
Alexa-Fluor-647-conjugated  anti-p-EGFR  antibody  (Y845).  The
levels of phosphorylated (A) and total EGFR (B) were analyzed by
flow  cytometry.  The  data  are  representative  of  at  least  three
independent  experiments.  Cells  cultured  under  serum-free
conditions were used as the control. C: western blot analysis of
ARPE-19 cells cultured to 80% confluence; treated with 2 μg/ml
tunicamycin, 30 mM glucose, or 5 mM GlcN in serum-free medium
for a further 24 h; then stimulated with EGF for 5 min.
explore whether the branching and levels of N-glycans on
EGFR were involved in the mechanism. The results of the
present study demonstrated for the first time that treatment
with  GlcN  at  concentrations  of  2.5  mM  and  5.0  mM
significantly  suppressed  the  EGF-induced  proliferation  of
ARPE-19 cells in a dose-dependent manner, and slowed the
cell-cycle progression of ARPE-19 cells through the G1–S and
G2–M  transitions  without  affecting  cell  viability.  The
antiproliferative effects of GlcN were confirmed in human
donor  cells.  This  study  also  provides  evidence  that  GlcN
modulated the level and branching of N-glycans on EGFR,
suppressed  EGFR  transactivation,  and  reduced  the
phosphorylation  of  ERK,  AKT,  and  STAT3.  Finally,  we
demonstrated that GlcN mediated these effects through the
EGF–EGFR signaling pathway.
GlcN suppresses EGF-induced proliferation of ARPE-19
and  human  donor  cells:  Our  findings  with  respect  to  the
activation of RPE cell proliferation are consistent with those
of  previous  studies,  indicating  that  RPE  cells  are  highly
responsive to EGF [4]. Khaliq et al. [9] showed that EGF could
stimulate the proliferation of RPE in vitro. Sugino et al. [8]
demonstrated that EGF and its signaling pathways are critical
factors that promote the survival, proliferation, adhesion, and
migration  of  RPE  cells  in  models  of  age-related  macular
degeneration. In addition, Chen et al. have shown that EGF
promoted expression of integrin-alpha(5) and the subsequent
proliferation and migration of ARPE-19 cells [12]. Our data
also show that GlcN effectively suppressed the proliferation
of ARPE-19 cells induced by EGF and added to the list of
cells,  the  proliferation  of  which  has  been  shown  to  be
suppressed by GlcN [15].
GlcN  suppresses  proliferation  of  ARPE-19  cells  by
delaying  the  cell  cycle  progression:  The  dose-dependent
suppression of EGF-induced proliferation of ARPE-19 cells
by GlcN observed in the present study could be partially
explained by an effect on the cell cycle mediated by EGF–
EGFR signaling. As we know, EGF is required for the G1–S
transition and DNA replication in different cell types [16,
17]. One study also found a novel EGF-sensitive checkpoint
at which EGF-dependent cells undergo delay in the G2–M
phase of the cell cycle before the activation of EGFR [18]. To
determine whether a nonspecific response to stress in the ER
contributed to the delay of cell growth, we examined the
expression of Hsp90, Grp78, and CHO-GADD, both markers
of ER stress. Our data showed that the expression of these
markers was only minimally altered in response to GlcN,
whereas  their  expression  was  markedly  increased  after
exposure of the cells to high concentrations of glucose or
thapsigargin. Although production of stress in the ER by GlcN
cannot  be  absolutely  ruled  out  by  our  data,  these  results
suggest that the effects of GlcN did not produce high levels
of nonspecific effects in the ER.
GlcN  delays  expression  of  cyclins  associated  with
progression of the cell cycle: To gain a better insight into the
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caused by GlcN, we evaluated its effects on several cyclins,
CDKs, and CDK inhibitors. In mammalian cells, mitogens
induce the expression of cyclin D and cyclin E, which are
sequentially assembled and activated with CDKs, and reduce
the amounts of the CDK inhibitor, p27, during G1. Cyclin D-
associated  CDKs  and  the  cyclin  E–Cdk2  complex  then
become  active,  phosphorylate,  and  inactivate  Rb.  After
release from the repression of Rb, E2F and its target genes,
such as those encoding cyclin A and several DNA replication
enzymes,  are  expressed.  These  events  mediate  cell-cycle
progression  through  G1  into  S  phase.  Other  studies  have
demonstrated  the  growth-inhibitory  effects  of  EGFR
inhibitors  or  anti-EGFR  antibody  [19].  We  observed  that
GlcN caused the delayed expression of cyclin A and cyclin E
and the delayed and prolonged expression of cyclin D, leading
to the accumulation of cells in G0–G1 phase, delayed cell-cycle
progression  at  the  G1–S  transition,  and  the  reduced
degradation of p27 in ARPE-19 cells. GlcN-treated cells also
exhibited slowed progression through G2–M phase or delayed
mitosis after release from an aphidicolin block. These results
again  suggest  that  GlcN  affects  EGF–EGFR  signaling  to
inhibit the proliferation of EGF-dependent cells.
GlcN reduces phosphorylation of EGFR and downstream
signaling molecules: The effects of EGFR signaling on cell
proliferation and survival are mediated by a complex network
of intermediates, including mitogen-activated protein kinase,
AKT,  and  STATs  [20].  The  binding  of  EGF  to  the
extracellular domain of EGFR induces dimerization of the
receptor and the activation of its intrinsic tyrosine kinase
activity,  leading  to  receptor  autophosphorylation  and  the
phosphorylation of tyrosine residues in various downstream
signaling molecules, including ERK1/2, AKT, STAT3, and
PKC [20]. Previous studies have shown that EGFR signaling
mediated  by  the  MEK/ERK  and  PI3K/AKT  pathways  is
essential  for  RPE  cell  proliferation  and  survival  [3].  One
molecule downstream from EGFR, STAT3, can trigger the
expression  of  target  genes  that  are  involved  in  cell-cycle
regulation, including cyclin D, p21, p27, and c-Myc [21].
Here, we have demonstrated that GlcN slightly reduced the
number of EGFR molecules on the surface of ARPE-19 cells
and greatly reduced their phosphorylation at the Y845 residue.
EGF is the most potent mitogen to cause the phosphorylation
Figure 9. Effects of glucosamine (GlcN)
on  the  expression  of  β-1,6-GlcNAc-
branched N-glycan in the human retinal
pigment epithelial cell line (ARPE-19)
cells and the regulation of ARPE-19 cell
proliferation  by  N-glycan  branching.
ARPE-19 cells at 80% confluence were
treated with 2 μg/ml tunicamycin, 30
mM GlcNAc, 30 mM glucose, 2.5 mM
GlcN, or 5 mM GlcN for 24 h. The cells
were  harvested,  incubated  with
fluorescein  isothiocyanate  (FITC)–L-
PHA  (10  μg/ml),  and  L-PHA  lectin
binding  was  analyzed  by  flow
cytometry. A: Binding of L-PHA lectin
to GlcN-treated cells are compared with
those in the positive (30 mM GlcNAc or
30  mM  glucose)  and  negative
(tunicamycin)  control  cells.  B:  The
effect of GlcN on L-PHA lectin binding
is dose-dependent. Cells were cultured
in serum-free medium containing GlcN
(2.5 mM or 5.0 mM) or high glucose
(Glc,  30  mM)  for  24  h.  C:  The
expression of epidermal growth factor
receptor  (EGFR)  in  ARPE-19  cells
treated with 2.5 mM or 5.0 mM GlcN or
30  mM  glucose  analyzed  by  western
blot. D: CFSE staining of human donor
retinal pigment epithelium (RPE) with
various levels of N-glycan branching.
The data are representative of at least
three independent experiments.
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2568of Y845 [22]. Because EGF is the only mitogen we used to
stimulate ARPE-19 cell proliferation, there should be no other
nonEGFR ligands to influence the phosphorylation of the
EGFR  Y845  residue.  Our  results  showing  that  the
phosphorylation of the downstream molecules ERK, AKT,
and  STAT3  in  EGF-stimulated  ARPE-19  cells  was  also
reduced,  providing  additional  evidence  that  this  EGFR
pathway was involved. The results of our assessment of the
inhibition of phosphorylation of STAT3 by GlcN are in good
agreement with those of Chesnokov et al. in human prostate
carcinoma cells, although GlcN induced apoptosis in that cell
line, an effect that was not observed in the RPE cells in our
study [15]. Our observation that GlcN can suppress the EGF-
induced increase in expression of β-catenin further supports
the conclusion that GlcN can effectively inhibit EGF–EGFR
signaling.
GlcN  regulates  EGF  effects  by  modifying  N-linked
glycosylation on EGFR: N-linked oligosaccharides are crucial
for  the  surface  levels  and  functions  of  membrane-bound
receptors for growth factors and cytokines [23]. The number
and complex degree of the branching of N-glycans cooperate
to regulate cell proliferation and differentiation [24]. Human
EGFR contains 12 typical N-glycosylation consensus sites. N-
glycan  functions  have  also  been  extensively  investigated,
showing their involvement in receptor sorting, ligand binding,
and dimerization [18]. Because GlcN is an inhibitor of the
biosynthesis  and  processing  of  N-linked  oligosaccharides,
and because it causes dramatic and reversible changes in the
nature of the lipid-linked oligosaccharides of glycoproteins
[16], we hypothesized that reduction in the branching and
levels of N-glycans on surface growth-factor receptors is a
possible  mechanism  of  action  by  which  GlcN  exerts  its
antiproliferative effect on ARPE-19 cells. Therefore, in the
present study, we evaluated the N-glycosylation of EGFR by
determining  its  binding  of  L-PHA,  a  plant  lectin  that
specifically binds β-1,6-GlcNAc-branched N-glycans, and its
molecular mass, which changes in a manner dependent on
levels of N-glycosylation [21]. We have demonstrated for the
first time that GlcN diminishes β-1,6-GlcNAc-branched N-
glycan expression in a dose-dependent manner and modulates
EGFR transactivation by reducing the level of N-glycans on
EGFR.
Possible  mechanisms  of  action  of  GlcN:  It  has  been
known  for  some  time  that  GlcN  alters  the  protein  and
nucleotide contents of cells [25], disrupts the structure and
function of the cellular membrane system [26], and modulates
the levels of plasma-membrane gangliosides [27]. However,
the  mechanism  for  the  antiproliferative  effect  of  GlcN  is
incompletely understood; and the complexity of the pathways
that  regulate  proliferation  and  the  varying  responses  of
different  cell  types  to  GlcN  suggest  that  more  than  one
pathway may be involved in its mechanism of action. Our
study extends our knowledge about the mechanisms by which
GlcN exerts its effects by demonstrating that, at least in these
ARPE-19 cells, it modulates the levels and branching of N-
glycans on the EGFR and inhibits EGFR transactivation and
the downstream phosphorylation of STAT3, ERK, and AKT
after stimulation with EGF.
Limitations  of  the  study:  We  confirmed  the
antiproliferative effects of GlcN in human donor cells; but we
used ARPE-19 cells for the other experiments, such as the
protein expression and lectin binding assays, because they are
easier to culture than primary human cells. We should point
out  that  although  this  cell  line  has  been  widely  used  for
experiments on RPE cells, several studies have shown that the
properties  of  ARPE-19  cells  vary,  depending  on  culture
Figure  10.  Effects  of  glucosamine
(GlcN)  on  the  expression  of
endoplasmic  reticulum  (ER)  stress
markers, Hsp27, Hsp70, Hsp90, Grp78,
and  CHOP-GADD.  Human  retinal
pigment epithelial cell line (ARPE-19)
cells were treated with 5 mM GlcN, 30
mM glucose or 1 μm thapsigargin (TG),
a pharmacological ER stress inducers as
a positive control, for 24 or 48 h. The
expression  of  ER  stress  markers  in
ARPE-19 cells was analyzed by western
blot.
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2569conditions  [28,29].  This  variability  extends  to  the
transcriptome of ARPE-19 cells [30], which is different from
those of native adult, native fetal, and cultured fetal RPE cells,
with 74 of 150 signature genes expressed at lower levels in
ARPE-19  cells  than  in  adult  native  RPE  cells  [31,32].
Therefore, our results should be considered provisional until
they can be repeated with cultures of nontransformed human
RPE cells. In addition, because the experiments described in
this  report  have  all  been  performed  in  vitro,  further
investigation is required to determine whether the results we
have observed are confirmed in vivo.
Conclusions: The results of our study may have bearing
on the pathogenesis and treatment of PVR. Both previous
findings  and  our  own  strongly  suggest  that  EGF,  which
activates the EGFR signal transduction pathway, plays a key
role in the pathogenesis of PVR. We have shown that GlcN
can suppress the proliferation of RPE cells, the main target
cells for the treatment of PVR. Our data support the hypothesis
that  GlcN  effectively  suppresses  the  EGF-induced
proliferation of ARPE-19 cells through modulation of the
branching  and  levels  of  N-glycans  on  surface  proteins,
including EGFR, and the inhibition of EGFR transactivation.
The results of our in vitro investigation suggest the possibility
that GlcN might play a role in the clinic as an agent for the
treatment or prevention of RPE-mediated ocular proliferative
disorders,  such  as  PVR,  and  other  EGF-dependent
proliferative cell-growth disorders. Further research into this
possible clinical application of GlcN is warranted.
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